肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2022 非小细胞肺癌HER2改变检查共识

2022-02-08 中国肿瘤科相关专家小组（统称） ESMO Open

非小细胞肺癌肺癌HER2改变检查

人表皮生长因子受体2（HER2）是一种具有细胞内酪氨酸酶活性的跨膜唐代白受体，其改变包括突变、扩张和过度表达，可能致癌。本文主要针对非小细胞肺癌HER2改变检查提供共识指导建议。

中文标题：

2022 非小细胞肺癌HER2改变检查共识

英文标题：

Consensus for HER2 alterations testing in non-small-cell lung cancer

发布机构：

中国肿瘤科相关专家小组（统称）

发布日期：

2022-02-08

简要介绍：

人表皮生长因子受体2（HER2）是一种具有细胞内酪氨酸酶活性的跨膜唐代白受体，其改变包括突变、扩张和过度表达，可能致癌。本文主要针对非小细胞肺癌HER2改变检查提供共识指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 非小细胞肺癌HER2突变检查共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=cb05e1c0023560bd, title=2022 非小细胞肺癌HER2改变检查共识 , enTitle=Consensus for HER2 alterations testing in non-small-cell lung cancer, guiderFrom=ESMO Open, authorId=0, author=, summary=人表皮生长因子受体2（HER2）是一种具有细胞内酪氨酸酶活性的跨膜唐代白受体，其改变包括突变、扩张和过度表达，可能致癌。本文主要针对非小细胞肺癌HER2改变检查提供共识指导建议。, cover=https://img.medsci.cn/2022214/1644816243467_1608702.jpg, journalId=0, articlesId=null, associationId=747, associationName=中国肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Tue Feb 08 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">人表皮生长因子受体2（HER2）是一种具有细胞内酪氨酸酶活性的跨膜唐代白受体，其改变包括突变、扩张和过度表达，可能致癌。本文主要针对非小细胞肺癌HER2改变检查提供共识指导建议。</span></p>, tagList=[TagDto(tagId=276, tagName=非小细胞肺癌), TagDto(tagId=428, tagName=肺癌), TagDto(tagId=122928, tagName=HER2改变检查)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5333, appHits=147, showAppHits=0, pcHits=702, showPcHits=5186, likes=1, shares=38, comments=4, approvalStatus=1, publishedTime=Mon Feb 14 15:22:00 CST 2022, publishedTimeString=2022-02-08, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Mon Feb 14 13:27:39 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 10:47:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 非小细胞肺癌HER2突变检查共识.pdf)])
2022 非小细胞肺癌HER2突变检查共识.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1217937, encodeId=4539121e93734, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a308153290, createdName=ms5000001487103078, createdTime=Sun May 08 20:28:54 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209997, encodeId=9cd4120999e19, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ff5497451, createdName=蓝莓兔子, createdTime=Sun Apr 10 10:53:26 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207558, encodeId=89cf120e55859, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:06:07 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207557, encodeId=f412120e557c7, content=赞，很新啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:05:51 CST 2022, time=2022-03-31, status=1, ipAttribution=)]
    2022-05-08 ms5000001487103078

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1217937, encodeId=4539121e93734, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a308153290, createdName=ms5000001487103078, createdTime=Sun May 08 20:28:54 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209997, encodeId=9cd4120999e19, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ff5497451, createdName=蓝莓兔子, createdTime=Sun Apr 10 10:53:26 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207558, encodeId=89cf120e55859, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:06:07 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207557, encodeId=f412120e557c7, content=赞，很新啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:05:51 CST 2022, time=2022-03-31, status=1, ipAttribution=)]
    2022-04-10 蓝莓兔子

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1217937, encodeId=4539121e93734, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a308153290, createdName=ms5000001487103078, createdTime=Sun May 08 20:28:54 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209997, encodeId=9cd4120999e19, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ff5497451, createdName=蓝莓兔子, createdTime=Sun Apr 10 10:53:26 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207558, encodeId=89cf120e55859, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:06:07 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207557, encodeId=f412120e557c7, content=赞，很新啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:05:51 CST 2022, time=2022-03-31, status=1, ipAttribution=)]
    2022-03-31 ms2000001047258750

    牛

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1217937, encodeId=4539121e93734, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a308153290, createdName=ms5000001487103078, createdTime=Sun May 08 20:28:54 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209997, encodeId=9cd4120999e19, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54ff5497451, createdName=蓝莓兔子, createdTime=Sun Apr 10 10:53:26 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207558, encodeId=89cf120e55859, content=牛, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:06:07 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207557, encodeId=f412120e557c7, content=赞，很新啊, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=039b5623994, createdName=ms2000001047258750, createdTime=Thu Mar 31 15:05:51 CST 2022, time=2022-03-31, status=1, ipAttribution=)]
    2022-03-31 ms2000001047258750

    赞，很新啊

    0

相关指南

2021 ESMO 临床实践指南的更新：早期和局部晚期非小细胞肺癌：侧重于诊断、分期、全身和局部治

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2021-09-01

中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）

国家癌症中心 · 2021-04-20

2021 加拿大共识建议：MET突变非小细胞肺癌的管理

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2021-11-09

2021专家共识：局部晚期非小细胞肺癌围术期免疫治疗

中国肿瘤科相关专家小组（统称） · 2021-09-10

非小细胞肺癌分子残留病灶专家共识

中国抗癌协会肺癌专业委员会 · 2021-06-30

老年非小细胞肺癌患者的免疫治疗：青年国际老年肿瘤学会立场文件

国际老年肿瘤学会(SIOG,International Society of Geriatric Oncology) · 2021-11-01